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Abstract
Importance in the Field—Phosphatases of Regenerating Liver (PRLs) are novel oncogenes 
that interact with many, well-established cell signaling pathways that are misregulated in cancer 
and is known to drive cancer metastasis when overexpressed.
Areas Covered in this Review—This review will cover basic information of the discovery 
and characteristics of the PRL family. We will also report findings on the role of PRL in cancer, 
cell functions, and cell signaling. Furthermore, PRL’s suitability as a novel drug target will be 
discussed along with current methods being developed to facilitate PRL inhibition.
Expert Opinion—PRLs show great potential as novel drug targets for anti-cancer therapeutics. 
Studies indicate that PRL can perturb major cancer pathways such as Src/ERK1/2 and PTEN/
PI3K/Akt. Upregulation of PRLs has also been shown to drive cancer metastasis. However, in 
order to fully realize its therapeutic potential, a deeper understanding of the function of PRL in 
normal tissue and in cancer must be obtained. Novel and integrated biochemical, chemical 
biological and genetic approaches will be needed to identify PRL substrate(s) and to provide 
proof-of-concept data on the druggability of the PRL phosphatases.
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1. INTRODUCTION
The addition and removal of phosphate groups is a highly conserved driving force in the 
regulation of cellular processes. A very precise balance between phosphorylation and 
dephosphorylation must be maintained in order for proper cell functions to be carried out. 
Protein kinases and phosphatases are the keepers of this balance with kinases adding 
phosphate groups and phosphatases removing them. As such, mutation and/or altered 
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regulation of these proteins have long been associated with disease making them tempting 
therapeutic and preventative targets. For many years, kinases have dominated the drug 
development industry with phosphatases generally being ignored until recently. 
Phosphatases were once thought to be non-specific and very difficult to study (1,2). 
However, improved technology and novel substrate-binding techniques began to provide 
mounting evidence showing that phosphatases are equally implicated in disease including 
cancer, diabetes, neurological diseases, and more (1). Novel methods for drug discovery 
have since been implemented to increase drug specificity by targeting unique structural 
features near the catalytic domain and regulatory sites (1,2). Consequentially, phosphatases 
have been brought into the spotlight in academic research as potential therapeutic targets.
Protein phosphatases are a diverse group of enzymes that defy attempts at simple 
classification. Generally, phosphatases can be divided into two superfamilies: enzymes that 
show specificity towards dephosphorylating serine and threonine residues (Ser/Thr 
phosphatases) and those that specialize in the dephosphorylation of tyrosine residues 
(Protein Tyrosine Phosphatases (PTPs)) (1). These two broad categories contain numerous 
families and subfamilies of proteins all of which are structurally unique and many of which 
are thought to have evolved independently from one another (1). A majority of phosphatase 
genes encode protein tyrosine phosphatases which can be identified by their HCX5R active 
site motif where the active site cysteine acts as the essential nucleophile during 
dephosphorylation (1,2). One of the largest and most diverse classes of PTP includes 
classical PTPs, which can be divided into Receptor-like and Non-transmembrane PTPs, and 
Dual Specificity Phosphatases (DSPs) (1). Dual Specificity Phosphatases are unique from 
the classical PTPs due to their ability to dephosphorylate both tyrosine and serine/threonine 
residues (1). DSPs tend to be very diverse from each other functionally, being able to 
dephosphorylate a wide variety of substrates (1). This review will focus on Phosphatases of 
Regenerating Liver, or PRLs, a family of novel DSPs, as potential drug targets for cancer 
therapy.
2. PRL Structural Features
PRL-1 was first discovered as a strongly up-regulated, immediate-early gene in regenerating 
rat liver (3). Later, its family members, PRL-2 and PRL-3, were identified by searching the 
Murine Expressed Sequence Tags database and were found to be highly similar in both 
amino acid sequence and structure to each other and PRL-1 (4). PRL-1 and PRL-2 were 
most similar in sequence, exhibiting 87% identity, while PRL-3 exhibited 76% and 79% 
identity to PRL-1 and 2 respectively (4,5). Further structural and sequential analysis allowed 
the PRLs to be categorized within the PTP superfamily (5,6). All the PRLs share the CX5R 
active site, P-loop, and WDP loop motifs typical of PTPs (5,6) (Figure 1). Structural 
similarities to PTEN, Cdc14, MKP, and other dual specificity phosphatases (DSPs) presents 
strong evidence that the PRLs are able to dephosphorylate both tyrosine and serine/threonine 
residues (5,6). One feature that makes the PRLs unique from all other phosphatases is the 
presence of a CAAX prenylation motif next to a polybasic region in the C-terminal domain 
(6,7). Prenylation, as discovered in studies of proteins like Ras and Rab, is known to 
facilitate localization of proteins to the plasma membrane (8). Indeed, both PRL-1and 3 have 
been found to associate with the plasma membrane and early endosome in mammalian cell 
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lines (9,10,11,12,13). PRL has also been shown to be regulated by the redox status of its 
active site and the formation of a disulfide bond when fully oxidized (14,15,16). Since its 
discovery, the PRL family has been studied extensively in cell culture and in several model 
animal systems.
3. Cellular Localization and Tissue Expression
In the cell, PRL will localize to the plasma membrane if the C-terminal CAAX motif is 
prenylated (7,8,13,). In HEK293 cells, PRL-1 constructs containing a mutated CAAX motif 
were found in the soluble cytoplasmic fraction whereas PRL-1 wild-type (WT) was found 
primarily in the membrane faction (7). This evidence showing that the CAAX domain is 
critical for membrane association coincides with studies with farnesyl-transferase inhibitor 
(FTI-277) based in NIH 3T3 cells stably expressing PRL-1,-2, or −3 (13). 
Immunofluorescent staining from both studies corroborated the conclusion drawn from the 
subcellular fractionation data and also revealed that a fraction of the PRL that was not 
prenylated had become localized to the nucleus (7,13). The polybasic region preceding the 
CAAX motif is hypothesized to be required for nuclear localization in the absence of 
prenylation and for recruitment to the membrane (8). When all six charged residues of the 
polybasic region were mutated to alanines, PRL did not localize to the plasma membrane or 
the nucleus but was found entirely in the cytosolic fraction (7).
Dumaual et al. conducted an extensive assessment of PRL-1 and −2 expression in human 
tissue samples. They found that PRL-1 and −2 were expressed almost ubiquitously across all 
tissues and organ systems with PRL-1 expression levels being slightly more restricted and 
less intense than PRL-2 (17). PRL-3 however, has a much more restricted expression 
pattern, primarily in the heart, skeletal muscle, vasculature, and brain, and is generally 
expressed at a lower level than PRL −1 and −2 (18). PRL-1 and −2 are also strongly 
expressed in the central nervous system (CNS) of developing Drosophila, amphioxus, and 
zebrafish (19). In mice, PRL-1 and −3 expression levels are much more restricted, showing 
expression in colon and intestine, but having very low or no expression in other organ 
systems (45,48).
4. Role of PRL in Cancer
PRL-3 was first brought into the spotlight as a potential oncogene in 2001(20). The study 
used samples of metastatic liver lesions from colorectal cancer (CRC) patients and applied 
serial analysis of gene expression (SAGE) technology to create a gene expression profile to 
compare to non-metastatic libraries (20). Of the 144 genes that were found to be 
misregulated in the metastatic lesions, PRL-3 was the most consistently up-regulated (20). 
Interestingly, the expression level of PRL-3 in colorectal cancer primary tumors was much 
lower than in corresponding hepatic metastatic lesions suggesting that PRL-3 may play an 
important role in metastasis as opposed to carcinogenesis (20). Subsequent studies showed 
that, while PRL-3 was more consistently elevated in liver and lung metastasis, many other 
types of CRC metastasis exhibited high PRL-3 expression including brain, ovary, and lymph 
node lesions (11). Furthermore, it was shown that high levels of PRL-3 expression in the 
CRC primary tumor could predict the presence of distant metastasis (11). A Kaplan-Meier 
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analysis for metastasis-free survival also revealed that patients with high levels of PRL-3 
expression in resected CRC primary tumors were at a greater risk for liver/lung metastasis 
than those with low PRL-3 expression (11). Interestingly, the prognostic value of PRL-3 
expression in CRC only correlates significantly in regards to risk of long distance metastasis 
and does not affect the presence of lymph node metastasis (11). Several more independent 
studies corroborate these findings (21,22). This suggests that PRL-3 may be useful for 
determining patient prognosis, allowing more judicious use of aggressive CRC therapies.
The original studies linking PRL-3 expression to CRC patient prognosis resulted in the 
discovery of similar findings in other types of cancer. Two studies show that PRL-3 
overexpression can be found in breast cancer. Radke et al. found elevated PRL-3 expression 
in 116 out of 135 (85.9%) samples of ductal carcinoma in situ (DCIS), and 190 out of 246 
(77.2%) samples of invasive carcinoma (12). Wang et al., on the other hand, found PRL-3 
overexpression in breast cancer, but in a smaller portion of samples (133 out of 382 
(34.8%)) (23). Radke et al. found that elevated PRL-3 in patients with node-positive breast 
cancer significantly impacted long term survival but did not significantly affect the survival 
of node-negative patients (12). Interestingly, Wang et al. found the opposite to be true, 
where PRL-3 overexpression was associated with reduced the life span of node-negative 
patients but not node-positive patients (23). Furthermore, a recent study by Hao et al. found 
PRL-3 overexpression in the primary tumor to be significantly correlated with breast cancer 
metastasis to the lymph node, while Wang et al. and Radke et al. reported that lymph node 
metastasis was independent of PRL-3 expression in the primary tumor (12,23,24). Further 
studies will be required to reconcile these conflicting results.
Along with the common colorectal cancer and breast cancer, PRL-3 has been shown to be 
up regulated in many other types of cancer. Up-regulated PRL-3 has been found in gastric 
carcinomas and was found to be significantly correlated to lymph node metastasis 
(25,26,27,28,29,30,31). Ovarian (32,33), liver (34,35), oral (36), cervical (37), esophageal 
(38), lung cancer (39,40), multiple myeloma (9,41), acute myeloid leukemia (AML) (42,43), 
and nasopharyngeal cancer (44) virtually all have been shown to exhibit high levels of 
PRL-3 expression. As with CRC, breast cancer, and gastric cancer, PRL-3 overexpression is 
overwhelmingly correlated with poor prognosis and progression to metastasis in all of the 
aforementioned cancer types (Table 1).
While there have been many studies investigating the role of PRL-3 in cancer, fewer have 
explored the relevance of PRL-1 and −2. Some of the earliest evidence of PRL-1 and −2 
involvement in human cancer came from a study focusing on the generation of PRL-3 and 
−1 monoclonal antibodies to be used to diagnose cancer metastasis. Li et al. tested PRL-1 
and PRL-3 specific antibodies on a human multiple cancer tissue array (45). The PRL-1 
antibody hit on 10 cancer tissues including renal carcinoma and ovary lymphoma (45). 
Wang et al. provided evidence that PRL-2 can serve as an oncogene in prostate cancer (46). 
In this study, PRL-2 was shown to be overexpressed in prostate cancer cell lines LNCaP, 
PC3, and DU145 and regulated tumor cell migration and invasion (46). Additionally, PRL-2 
transcription was found to be elevated in three samples of advanced prostate cancer in 
comparison to the corresponding normal prostate tissue (46). In situ hybridization of PRL-2 
antisense oligonucleotide also showed PRL-2 elevation in four tumor samples in comparison 
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to four samples of benign prostatic hyperplasia (46) (Table 1). Recently, a study by 
Dumaual et al. showed that both PRL mRNAs are highly to moderately expressed in all but 
six tumor tissue samples examined (47). Furthermore, PRL −1 and −2 mRNA was found to 
be more overexpressed in poorly differentiated tumors in comparison to well differentiated 
tumors (47).
The role of PRL in cancer has also been studied in animal models. A conditional PRL-3 KO 
mouse was created to study the effect of PRL-3 loss on azoxymethane (AOM)-dextran 
sodium sulphate (DSS) induced tumorigenesis (48). A one-time treatment with the 
carcinogen AOM followed by long term inflammation induced by DSS is a well-established 
protocol for inducing colorectal carcinogenesis for study in murine model systems (48). 
Cohorts of WT and PRL-3 KO mice were subjected to AOM-DSS treatment for 12 to 16 
weeks (48). The tumors in the colons of the two cohorts were similar in size but PRL-3 KO 
mice had significantly fewer tumors at 16 weeks treatment than WT mice (48). These results 
provide evidence implicating PRL-3 in colon carcinogenesis. The involvement of PRL-2 in 
cancer was evaluated in breast cancer–prone MMTV-ErbB2 transgenic mice (49). MMTV-
PRL-2 transgenic mice engineered to overexpress PRL-2 in mammary tissue did not exhibit 
spontaneous tumorigenesis, but they exhibited an accelerated development of mammary 
tumors initiated by introduction of an MMTV-ErbB2 transgene (49). The results support that 
PRL-2 plays a role in breast cancer progression.
5. Cell Function
PRL-1 was originally identified as an immediate early gene, whose expression was induced 
during liver regeneration after partial hepatectomy (50). Subsequently, PRLs were found to 
be elevated in many tumor cell lines, and cells expressing high levels of PRLs exhibited 
enhanced proliferation and anchorage-independent growth (8, 50, 51, 52, 53, 54).
It became clear from accumulated studies in human metastatic lesions that PRL-1, −2, and 
−3 also play an important role in cancer progression. The first insights to the molecular basis 
for PRL involvement in metastasis and cancer was from a study published in 2003 (22). 
Using a Chinese Hamster Ovary (CHO) cell line stably expressing Myc-tagged-PRL-1, −3, 
or β-Gal (control), the authors ascertained the effect of PRL-1 and −3 overexpression on cell 
mobility and cell invasiveness (22). PRL expressing cells were found to be significantly 
more mobile and invasive than the controls (22). Additionally, cells expressing a 
catalytically inactive mutant PRL showed significantly less activity and movement than WT 
controls, confirming that PRL-3 played an important role in cellular migration and that its 
ability to induce migration is dependent on its phosphatase activity (22). To assess whether 
or not cells overexpressing PRL could induce metastatic lesions, Myc-PRL-1, −3, and β-Gal 
CHO cells were injected into the tail vein of ten-week-old female nude mice (22). All mice 
that received injections of either myc tagged PRL-1 or PRL-3 developed numerous lung 
metastases while none of the control mice injected with cells expressing β-Gal cells 
developed tumors (22). These results were the first to show that PRL overexpression could 
induce metastasis in vivo. Several papers were published later with similar results in both 
mouse melanoma and HEK293 cells lines (5,9,50,55,56,57,58,59). All studies showed 
evidence that increasing PRL-3 expression in cells resulted in increased cell adhesion, 
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migration, invasiveness, and proliferation both in vivo and in vitro. The oncogenic effect 
was also shown to be dependent on PRL-3 phosphatase activity, as no phenotype was 
observed when cell were transfected with PRL-3 constructs whose active site was mutated 
(60). Sun et al. extended this further by showing that PRL trimerization and the presence of 
the C-terminal polybasic regions were also required to incite the oncogenic phenotype (7). 
For some time after the discovery of the PRLs, most of the interest had been focused on 
PRL-3 and −1. Recently, however, a study by Wang et al. revealed that PRL-2 can also 
affect cell migration and invasion (46). When PRL-2 was knocked down by short hairpin 
RNA (shRNA) or siRNA, A549 cells (a lung cancer cell line that naturally has high PRL 
expression) migrated slower through Transwell migration and Matrigel invasion chambers 
than control cells did (46). This effect could be rescued by transfecting a siRNA-resistant 
mutant PRL-2 construct into cells with (siRNA) silenced PRL-2 (46). Also, like PRL-1 and 
−3, PRL-2 constructs with mutated catalytic sites and/or CAAX domains could not induce 
increased cell migration and invasion (46).
Along with cell migration, invasion, adhesion, and proliferation PRLs have been shown to 
affect cell apoptosis and angiogenesis. Three papers reveal a novel connection between 
PRLs and p53. Basak et al. show that PRL-3 is up-regulated in a p53-dependent manner 
after submitting control and Doxorubicin (DNA damaging agent)-treated murine embryonic 
fibroblast (MEF) cells to a microarray analysis (61). A scan of the PRL-3 locus revealed two 
p53 binding sites, one of which p53 was shown to bind to directly via chromatin 
immunoprecipitation (61). PRL-3 expression in MEFs result in fewer BrdU positive cells 
which is indicative of cell cycle arrest (61). PRL-3 overexpression was also able to arrest 
HT1080 cells but failed to arrest RKO and U2OS cancer cells (61). The molecular 
mechanism for cell cycle arrest was shown to be dependent on increased Akt activation via 
overexpression of PRL-3, followed by negative feedback regulation of the PI3K/Akt 
pathway and subsequent transcription of growth arresting genes (specifically Foxo, p21, and 
p27) (61) (Figure 2). Surprisingly, Basak et al. found that knocking down PRL-3 did not 
produce the opposite effect, but instead resulted again in cell cycle arrest (61). Since down-
regulating PRL-3 in p53-null MEF cells did not reproduce this effect it was concluded cell 
cycle arrest in PRL-3 ablated cells was due to increased p53 activity (61). Furthermore, 
p19Arf was found to be up-regulated in PRL-3 ablated MEF cells providing a potential 
molecular mechanism for p53-dependent cell cycle arrest via p19Arf sequestration of 
MDM2 (negative regulator of p53) (61) (Figure 2).
Two papers by Min et al. showed that p53 could also be regulated by PRL-1 and −3 in 
cancer cells (Table 2). Up-regulation of PRL-1 and −3 can both inhibit p53 and p53-
mediated apoptosis individually with the opposite being true when PRL-1 or −3 is knocked 
down (62,63). Western blot analysis of PRL-1 or −3 overexpressing cells reveals that 
apoptosis inhibition can be caused by PRL-mediated activation of MDM2 via PI3K 
activation and PIRH2 (p53 ubiquitinase) transcription via EGR1 activation (62,63) (Figure 
2). Min et al. did not encounter the same cell cycle arrest phenotype that was discovered by 
Basak et al., however, this may be explained by carcinogenic defects in cancer cell lines 
used by Min et al (62,63).
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PRL-3 has been found to be strongly expressed in tumor vasculature and noted by many 
early PRL studies that it may play a role in induction of angiogenesis (5,35,60,64,65). Early 
studies have shown that PRL-3 overexpression in human umbilical vascular endothelial cells 
(HUVEC) can induce tube formation and a recent paper by Xu et al. explored the molecular 
mechanism in detail (66). In this study, vascular endothelial growth factor (VEGF) is shown 
to induce the transcription of PRL-3 in HUVEC cells via MEF2C transcription factor 
(Figure 2), which was shown to bind to the PRL-3 promoter both in vitro and in vivo (66). 
Furthermore, VEGF could not induce PRL-3 expression when MEF2C was knocked down 
by siRNA and PRL-3 knockdown in HUVEC resulted in compromised tube formation (66).
6. Signaling mediated by PRL
Since its discovery as an oncogene in colorectal cancer, PRL-3 has been exhaustively 
researched in cell culture. The most confounding factor in many of these studies is the lack 
of a putative substrate. Despite this PRL-3 has been shown to alter several major cell 
signaling pathways, including PTEN and Src, making it an alluring target for study and 
cancer treatment (Summarized in Table 2). One of the first mechanistic pathways to be 
associated with PRL is Src and its downstream targets (Figure 2.). A study by Liang et al. 
showed that when PRL-3 was overexpressed in HEK293 cells Src kinase activity was 
increased by 180% in comparison to control and PRL-3 C104S mutant cells (54). 
Downstream targets ERK1/2, STAT3, and p130Cas also experienced increased 
phosphorylation, which is consistent with increased Scr activity (54) (Figure 2). Purified 
PRL-3 was not able to phosphorylate Src directly; however, Csk protein (negative regulator 
of Src) expression was shown to be significantly reduced in cells overexpressing PRL-3 (54) 
(Figure 2). Indeed, when Csk was reconstituted to normal levels, via tetracycline expression 
in cells overexpressing PRL-3, Src phosphorylation and the oncogenic phenotype of PRL-3 
was negated (54). A follow up study on the activity of PRL-3 on Csk revealed that PRL-3 
could inhibit Csk translation due to increased phosphorylation of Ser-51 of eIF2α (67). 
Subsequent studies indicated that PRL-1 can also activate Src and its downstream targets 
(67,68). Unlike PRL-3, PRL-1 activation increased Tyrosine 416 phosphorylation as 
opposed to Tyr527 and increased FAK activation along with pre-established p130Cas, 
ERK1/2, and STAT3 (68) (Figure 2). Furthermore, active forms of matrix 
metalloproteinases 2 and 9 (MMP 2 and 9) were expressed at higher levels than in control 
cells (68). MMP2 and 9 are regulated by ERK1/2, can degrade collagen of the basement 
membrane, and are often found overexpressed in cancer, providing another mechanism by 
which PRL can induce cell migration/invasion (68) (Figure 2).
A study by Fiordalisi et al. shows that PRLs can regulate Rho and Rac activity in SW480 
cells (10) (Figure 2.). Rho A, C, and Rac are known to promote actin polymerization 
associated with cell mobility (10). In cells that have been transfected with PRL-1 and −3 
overexpression vectors, RhoA, and RhoC expression levels increased by 4- to 7-fold while 
Rac was reduced 60 to 70 percent (10). Further testing showed that, in order to promote cell 
invasion and mobility in a Rho-dependent manner, the presence of Rho effector ROCK and 
PRL phosphatase activity is required (10). This report correlates with other studies that 
assert that PRL can affect actin cytoskeleton dynamics (69).
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PRL is also known for interacting with adhesive proteins to modulate cell migration and 
invasiveness (69,70). It has been shown that PRL can interact with integrin proteins 
(71,72,73,74,75) (Figure 2). When up-regulated, PRL can dephosphorylate integrin β, 
enhancing integrin β binding with Src kinases (which, in turn, decreases the coupling of 
integrins to actin and impairs integrin-mediated adhesion) (73, 74, 75). Furthermore, PRL 
overexpression has been shown to suppress integrin α (but not integrin β) expression levels 
(71,72,73,74). The down-regulation of integrin α by PRL-3 is hypothesized to be carried out 
via inhibition of c-fos and that integrin α binding to PRL can inhibit its interaction with the 
β subunit (71,72,73,74). E-cadherin, γ-catenin, and vinculin are also down-regulated with 
PRL-3 over-expression, while mesenchymal markers fibronectin and Snail are up-regulated 
(70). The adhesive proteins are upstream of PI3K/Akt, which has been shown to be up-
regulated in DLD-1 cells overexpressing PRL-3 (70) (Figure 2). The mechanism for this 
action may be the result of PTEN downregulation (70). PTEN is a negative regulator of the 
PI3K pathway and is down-regulated in DLD-1 cells over-expressing PRL-3 (70). PRL-2’s 
ability to suppress PTEN level and promote PI3K/Akt pathway activation is also 
documented in PRL-2 deficient murine models (76,77).
PRL-mediated Src and PTEN/Akt activation can also be explained by upstream activity with 
receptor tyrosine kinases (RTKs) (Figure 2). PRL-3 has been shown to up-regulate PDGFR, 
Eph, and integrin receptor array in a proteomic analysis of HEK293 cells overexpressing 
PRL-3 (75). Phosphoproteomic data support intracellular activation of an extensive 
signaling network normally governed by extracellular ligand-activated transmembrane 
growth factor, cytokine, and integrin receptors in the PRL3 cells (75). Another study also 
revealed evidence of PRL-3 induced activation of EGFR in A431 epidermoid carcinoma 
cells (78). PRL-3 overexpression induced a state of EGFR addiction in both cell lines and in 
patient tumor sample, causing hypersensitivity to EGFR inhibition (78). It was concluded 
that PRL-3 regulates EGFR by transcriptionally down-regulating PTP1B, causing EGFR 
hyperphosphorylation and activation (78) (Figure 2). These studies are of particular note due 
to the fact that the effect of PRL-3 on receptor tyrosine kinases is able to explain and 
corroborate established PRL literature that PRL alters Src/ERK, PI3K/Akt, and actin/
adhesive protein dynamics (75,78).
Several independent studies also show that PRL effects some additional pathways including 
upregulation of KCNN4 potassium channels (79), activity toward phosphoinositides (80), 
induction of micro RNAs (miR) 21, 17, 19a (81), and interaction with miR-495 and 
miR551a (82). One study proposes a novel role of PRL-3 downstream of an internal tandem 
duplication mutant of fms-like tyrosine kinase 3 (FLT3-ITD) present in approximately 25% 
of AML patients (43). In an attempt to rectify FLT3-ITD-positive AML drug resistance, 
Zhou et al. treated AML cell lines with both FLT3 inhibitor ABT-869 and a histone 
deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) and were successful in 
reducing AML colony formation and inducing apoptosis in tumor cells (43). Further studies 
revealed that PRL-3 was strongly downregulated in cells that received combined ABT-869 
and SAHA treatment and showed evidence that PRL-3 may be responsible for FTL3 drug 
resistance through activation of the Stat-pathway, interaction with histone deacetylase 4, and 
upregulation of Mcl-1 (a protein that has been shown to incite tumor development and 
maintenance in many different cancers including hematological malignancies) (Figure 2.) 
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(43). In light of this evidence, PRL-3 may prove to be a potent target for treatment of drug-
resistant AML.
7. Physiological Roles of PRL
In order to study the physiological role of PRL in normal and cancerous tissue several 
genetically modified model organisms were created. Deletion of PRL2, the most 
ubiquitously expressed PRL family member, leads to retarded growth at both embryonic and 
adult stages. (76). This finding is congruent to evidence presented by previous studies that 
PRL plays a role in cell proliferation. Interestingly, another phenotype made itself evident in 
the PRL-2 KO lines in the form of placental hypotrophy in females (76). 
Immunohistochemistry staining of Ki67 revealed that placental hypotrophy was caused by a 
reduction of cell proliferation, especially in the spongiotrophoblast layer (76). Glycogen 
cells were also significantly reduced in the PRL-2 KO placenta raising the possibility of a 
nutrient defect in PRL-2 KO fetuses (76). Western Blot analysis of the whole placenta lysate 
showed a 70% decrease in Akt phosphorylation along with a 1.7-fold increase in PTEN in 
KO mice in comparison to WT (76). This data was corroborated in HEK 293 cells 
overexpressing PRL-2 (in this case the effect on PTEN and Akt phosphorylation was the 
reverse of that in placental tissue) (76). Furthermore, severe and progressive loss of fertility 
as well as hypotrophic testis were observed in male PRL-2 KO mice (77). Within the testis, 
spermatogenesis occurs in seminiferous tubules, which normally have a very distinct cellular 
structure with spermatogonia stem cells lining the basal lamina, followed by primary and 
secondary spermatocytes, and terminating with mature spermatids ready to be ejected into 
the lumen (Figure 3) (83). Mature sperm are then drained into the epididymis where they are 
stored until ejaculation (83). Histological cross-sections of PRL-2 KO seminiferous tubules 
show reduced cellularity in comparison to WT mice accounting for the small testis size (77). 
By the time the mice reach six months of age, male fertility and sperm count is severely 
reduced and testis cross-sections show large sections of seminiferous tubules that have 
completely shed their germ cells into the lumen (Figure 3) (77). Unlike the placenta 
however, the KO testis showed no decrease in cell proliferation (77). Instead, the cause of 
testicular atrophy in PRL-2 KO mice was due to a significant increase in apoptosis (77). 
This led to the hypothesis that the loss of fertility and hypo-cellularity of the testis was due 
to a failure to maintain spermatogonia stem cells as a direct result of the loss of PRL-2 (77). 
Furthermore, c-kit signaling, which is responsible for maintaining the self-renewal of 
spermatogonia (84), was also found to be attenuated in a post-transcriptional manner in 
PRL-2 null germ cells. PTEN, a negative regulator of c-kit signaling, was elevated in PRL-2 
null germ cells (Figure 2) (84,77). More recent studies reveal that PRL-2 deficiency also 
impairs hematopoietic stem cell (HSC) self-renewal (85). Moreover, PRL-2 null 
hematopoietic stem and progenitor cells (HSPCs) are more quiescent and show reduced 
activation of the Akt and ERK1/2 signaling as a result of an increase in PTEN level (85). 
Furthermore, PRL-2 is found to be important for SCF-mediated HSPC proliferation and loss 
of PRL-2 decreased the ability of oncogenic KIT/D814V mutant to promote hematopoietic 
progenitor cell proliferation (85). Thus, PRL-2 plays critical roles in regulating HSC self-
renewal and mediating SCF/Kit signaling (85,77). Together these findings establish that 
PRL-2 is required for a number of developmental processes (placenta formation, 
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spermatogenesis, HSC self-renewal) and reveal a novel mechanistic connection between 
PRL-2 and PTEN (76,77,85). Given the strong cancer susceptibility to subtle variations in 
the level of PTEN, the ability of PRL-2 to repress PTEN expression qualifies it as an 
oncogene and a novel target for developing anti-cancer agents.
8. Strategies to target PRL
Given the roles of PRL in tumor progression and metastasis, there is increasing interest in 
targeting the PRLs for novel anti-cancer agents. Although PRL’s wide and shallow active 
site makes inhibitor specificity with small molecules very difficult, several small molecules 
have been reported to inhibit PRL activity. The most noteworthy is compound 1 (Figure 4), 
which was identified from a high-throughput screen of the Roche chemical library (86). 
Compound 1 inhibits all PRLs with IC50 values in the 100–300 nM range (86). It exhibits 
very high selectivity toward the PRLs, with minimal activity when tested in vitro against a 
panel of 11 other phosphatases (86). Furthermore, compound 1 is able to inhibit anchorage 
independent cell growth of colon cancer cells and suppress the migration of HUVEC cells, 
through a mechanism involving proteolytic cleavage of p130Cas (86). Compound 2 (Figure 
4), a benzylidene rhodanine derivative, inhibits PRL-3 activity with an IC50 of 0.9 µM [2] 
(87). Compound 2 is able to block the invasion of B16F19 mouse melanoma cells, which 
express high levels of endogenous PRL-3 (87). An anthraquinone derivative, emodin 
(compound 3, Figure 3), inhibits PRL-3 and reduces cell migration and invasion of PRL-3-
DLD-1 colon cancer cells (88). A biflavonoid (ginkgetin, compound 4, Figure 4) extracted 
from Taxus cuspidate also showed moderate PRL-3 inhibitory activity (89). Finally, 
compound 5 (Figure 4) was identified as a PRL-3 inhibitor using a structure-based virtual 
screening approach (90). Although some of these compounds can serve as promising leads 
for further development, further studies are required to correlate PRL inhibition with the 
anti-tumor activity.
An alternative to inhibition of the phosphatase activity is interference with PRL 
trimerization. One interesting and unique feature of PRL-1 is that it forms trimers in 
crystalline state (7,91) (Figure 1). The domain on which trimerization occurs is away from 
the active site and on the structurally conserved C-terminal end (7,91). Crosslinking 
experiments using HA-tagged PRL-1 and PRL-3 showed that PRL does indeed form trimers 
inside the cells (7). Furthermore, trimerization was shown to be essential for PRL function 
(7). When PRL-1 proteins with mutated residues on the trimerization domain were stably 
overexpressed in cells lines the oncogenic increase in cell proliferation and migration due to 
PRL overexpression was rescued (7). Mutation of the trimer interface residues did not 
impede the ability of PRL-1 to associate with the membrane nor did the concentration of 
PRL-1 affect the catalytic rate constant in vitro (7). The notion that one can disrupt the 
function of a PTP by targeting trimerization and other unique regulatory domains instead of 
the catalytic site is a novel and exciting concept, since many of the active sites of PTPs are 
conserved and it can be difficult to obtain a drug that is specific for a single PTP (1,2).
Another method of therapeutically targeting PRL proteins is through the use of specific 
antibodies. For many years chemical inhibition or stimulation has dominated the medical 
field as the premier method for treating cancer and other diseases. Within the past decade, 
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however, new and exciting methods of treatment have emerged in the form of gene therapy 
and antibody treatment (92). The use of antibodies as a powerful diagnostic tool and as a 
way to use the body’s own immune system to combat disease has become one of the hottest 
fields of therapeutic research (92). Three proof-of-concept papers show that injectable 
antibodies against intracellular PRL-1 and PRL-3 are able to prevent experimental 
metastases when mice are injected with cancer cells that express high PRL [92,93,94]. Mice 
with PRL-1 or −3 overexpressing cells had larger tumors in comparison to WT and vector 
controls (92,93,94). When treated with PRL-1 or −3 antibody, however, the tumor size 
became dramatically reduced (92,93,94).
9. Conclusion
The PRL family consists of novel DSPs found to be overexpressed in many cancers. The 
main cellular mechanisms of PRL in cancer is to induce cell proliferation, survival, invasion, 
and epithelial to mesenchymal transition. Due to the fact that PRL plays a causative role in 
cancer progression and metastasis and affects so many important oncogenic and tumorigenic 
pathways it makes for a very tempting therapeutic target for cancer treatment and possibly 
other conditions (i.e. male fertility). Some success has been made using small molecules to 
target PRL as well as two novel approaches. Overall, PRL shows much potential for 
development as a drug target.
10. Expert Opinion
Phosphatase of Regenerating Liver is a promising, novel oncogene in the field of cancer 
research. Increasing amounts of evidence indicate that PRLs interact with important 
oncogenes and tumor suppressors such as PTEN, p53, and Src and show much promise as a 
cancer therapy target. In addition to small molecules aimed at the active site, therapeutic 
targeting of the trimer interface for PRL inhibitor development and the use of PRL-specific 
antibodies are both novel and promising strategies for PRL-based anti-cancer agents. 
However, there is much work to be done before treatment in human cancer patients can be 
considered. The most significant hurdle that needs to be overcome before we can reach a 
genuine understanding of the function of PRL is the lack of a putative substrate. Many 
potential substrates and pathways have been proposed but none have been confirmed by 
dephosphorylation with PRL using traditional enzyme assays. The reason for this may be, as 
stated above, due in part to PRL’s relative inactivity in vitro. PRL is known to associate with 
the plasma membrane and that this association is necessary for its function as a protein 
phosphatase. The reason for its inactivity in vitro may indicate that PRL requires molecular 
interactions that can only be attained in a complex, by the formation of PRL trimers, or with 
an as of yet unidentified co-factor. However, in vivo substrate trapping is a viable method 
for discovering the substrate(s) of PRL when combined with mass spectrometry and cell-
based assays (95). These trapping mutants are made by mutating key residues in the catalytic 
domain such that the enzyme can recognize and bind to its substrate but cannot 
dephosphorylate and release it (95). The in vivo method involves either a transient or stable 
transfection of tagged, substrate trapping mutant plasmids into a living cell to incubate 
before lysis and extraction of the mutant protein via immunoprecipitation (95). For the in 
vitro method, the mutated protein is tagged and conjugated to beads and then applied to cell 
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lysate where it is incubated with free floating proteins (95). There are advantages and 
disadvantages to both methods. The in vivo method allows for the mutated protein to 
interact with substrates in a physiologically relevant cellular environment but can be 
difficult to scale up enough to achieve a novel and observable substrate band, especially if 
the substrate is not abundant in normal cellular conditions (95). Conversely, the in vitro 
method is easy to scale up for mass spectrometry or western blot analysis but may cause 
non-specific interactions (95). Practically, both methods are used, along with mass 
spectrometry and cell assays to maximize the chance of capturing and identifying a 
physiological substrate.
Another hurdle that confounds the ability to effectively study the PRLs is, in fact, their 
significant homology to each other. In terms of the effort to dissect the physiological role of 
PRL, no antibody exists as of yet that can completely differentiate between PRL-1 and 2 
making it difficult to determine differential protein expression and function between the two. 
Also, since the PRLs may have similar and potentially overlapping roles, isoform specific 
knockout mice would be very useful to dissect PRL functions. Knockout mouse models for 
PRL-2 and PRL-3 have recently been reported (48,76) and it is likely that a PRL-1 knockout 
model will be available in the near future. Crossing these strains to generate multiple null 
mutations could add considerable insight into the in vivo function of this gene family.
In conclusion, there is a lack of detailed knowledge regarding the physiological function of 
PRLs that needs to be resolved before clinical drug development can be attempted. 
However, the ability to target and inhibit PRLs in vivo is invaluable in the effort to dissect 
the physiological function of these important oncogenes and to evaluate the therapeutic 
potential of targeting the PRLs. PRLs have been shown to greatly impact cellular growth, 
apoptosis, stem cell renewal, and can regulate several important oncogenes, tumor 
suppressors, and regulators of metabolism. Furthermore, there is evidence in murine models 
that PRL is critically important for proper embryonic development and cancer progression. 
The knowledge gained from studying the physiological and mechanistic aspects of PRL will 
be essential in facilitating the development of new therapeutic strategies for cancer and other 
diseases.
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Highlights
• Phosphatases of Regenerating Liver are novel, dual specificity phosphatase and 
oncogenes
• PRLs are found significantly overexpressed in many cancers including 
colorectal cancer, breast cancer, and gastric carcinoma.
• PRLs have been shown to interact with major oncogenic and tumor suppressor 
cell signaling pathways such as PTEN, PI3K/Akt, p53, and Src.
• PRL plays a role in number of developmental processes (placenta, 
spermatogenesis, hematopoietic stem cell self-renewal).
• PRL can be inhibited by active site-directed inhibitors as well as novel strategies 
that include vaccination by antibodies and disruption of PRL trimerization.
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Figure 1. 
A. Ribbon Diagram of the Structure of PRL-1: The C-terminal end of PRL contains the 
CAAX prenylation domain and adjoining polybasic region and has been shown to be vital to 
PRL phosphatase activity. This structure shows the active site sequence, which is located on 
the P-loop, containing the catalytic Cysteine (6). The WPD-Loop contains Asp72 which acts 
as a general acid during catalysis (6). The WPD-Loop of PRL contains some variations from 
other PTPs that may account for low, in vitro activity (6). One difference is that the 
conserved serine or threonine placed after the invariant Arginine in most PTPs is replaced 
by an Alanine in PRL (6). PRL also lacks key hydrogen bonds that are known to stabilize 
the P-Loop of other PTPs for catalysis (6). The Q-Loop is important for hydrogen bonding 
with scissilie oxygen and active site water molecule (6). B. PRL Trimer: PRL crystalizes in 
a trimer that fixes the C-Terminal ends of each monomer such that they all face towards the 
plasma membrane. This trimer is oriented with the C-terminal ends facing out (into the 
“membrane”) with the active sites on the opposite face (in the “cytoplasm”). This is how the 
PRL trimer is hypothesized to dock onto the membrane. The trimer state has been shown to 
be physiologically relevant and targetable for disassociation.
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Figure 2. 
Cell Signaling Pathways Regulated by PRLs: A summarization of the most important 
oncogenic and tumor suppressive pathways that PRL has been shown to effect including 
Src/ERK1/2, p53, PTEN/PI3K/Akt, Adhesion proteins, and growth factor receptors.
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Figure 3. 
Spermatogenesis and PRL-2 depletion: A. Healthy seminiferous tubule cross-section of a 3-
month old male mouse. The seminiferous tubules sport a distinct cellular structure. a: Basal 
Lamina, b: Spermatogonial cells, c: Primary Spermatocytes, d: Secondary spermatocytes, e: 
Spermatids and mature sperm about to eject into the lumen, F: Lumen and maturing sperm 
tails. B. This is the seminiferous tubule of a 6-month old PRL-2 KO mouse. This cross-
section shows complete shedding of the germ cells into the lumen (as indicated). C. 
Spermatogenesis procession.
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Figure 4. 
Small molecule PRL inhibitors. Compounds 1–5 as described in the text.
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Table 2
Summary of potential PRL effector molecules.
PRL effector
molecule
Effect of PRL
Overexpression
Reference
p53 Inhibition (62,63)
Src Activation (54,67,68)
ERK1/2 Activation (54,67,68)
STAT3 Activation (54,67,68)
p130Cas Activation (54,67,68)
Csk Inhibition (54,67)
MMPs Activation (68)
FAK Activation (PRL1) (68)
Rho A and C Activation (10)
Rac Inhibition (10)
Integrin α Inhibition (71,72,73)
Integrin β Enhance Src
interaction
(73,74,
75)
c-fos Inhibition (71)
Actin
Cytoskeleton
Uncoupling from
adhesive proteins
(69)
E-Cadherin Inhibition (70)
γ-catenin Inhibition (70)
Vinculin Inhibition (70)
Fibronectin Protein level Up-
regulation
(70)
Snail Protein Level Up-
regulation
(70)
PTEN Inhibition (70,76,77)
Akt Activation (70,76,77)
PDGFR Activation (75)
Eph Activation (75)
EGFR Activation (78)
PTP1B Inhibition (78)
KCNN4 Activation (79)
Phosphoinositides Dephosphorylation (80)
miR 21,17,19a Induction (81)
miR 495, 551a Induction (82)
STAT5 Activation (43)
Histone
Deacetylase 4
Activation (43)
Mcl-1 Induction (43)
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